Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
Date:2/10/2011

curities during 2010 and a one-time $1.4 million loss recognized on auction rate securities in 2009.

2011 Financial GuidanceThe Company expects to have a net cash burn from operations of approximately $3 to $6 million in 2011. Revenue is expected to increase to approximately $75 to $80 million which includes amortization of up-front license fees of approximately $36 million and anticipated milestones earned under collaboration agreements of approximately $30 million. Expenses for 2011 should approximate $44 to $48 million. Net income for 2011 is expected to be $34 to $39 million, or $0.62 to $0.71 cents per share based on 55 million basic shares outstanding. The Company expects to end 2011 with approximately $130 million in cash, investments and receivables.

Pipeline HighlightsElagolix UpdateAbbott and Neurocrine requested an end of Phase II meeting last year and the companies are scheduled to meet with the FDA in March 2011. The Companies are currently preparing the briefing document for the FDA meeting. This document will encompass the entirety of the elagolix endometriosis program thus far including, twelve Phase I studies and six Phase II studies in over 1,000 subjects for up to six months of continuous treatment. Upon receipt of the written minutes of the March 2011 meeting, the Company will provide an update as to the timing around the elagolix clinical program.

Urocortin 2 UpdateThe Christchurch Cardioendocrine Research Group at University of Otago, Christchurch School of Medicine and Health Sciences, New Zealand, in collaboration with the Company, is enrolling patients with Acute Decompensated Heart Failure in a Phase II study of urocortin 2, and has enrolled 39 patients as of mid-January, of a planned total patient population of 50.

Additionally, urocortin 2 studies are underway at the Centre for Cardiovascular Sciences at The University of Edinburgh through a British Heart Foundation grant. Nine studies are expec
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
2. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
3. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
4. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
8. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
9. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
10. Neurocrine Biosciences Amends Corporate Headquarters Lease
11. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... is rarely simple. From crop yields to disease risks, ... those considered "complex traits." Just as for heightthe textbook ... particular human disease are shaped by multiple genetic and ... involved. To track down such genes, geneticists typically mate ... large mouse and a small mouseand then study their ...
(Date:9/19/2014)... 2014  An entire month is dedicated to one ... Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease affecting ... atrophy, weakness, and foot and hand deformities. CMT affects ... CMT is a progressive disease, and over time patients ... devices such as leg braces, wheelchairs and scooters to ...
(Date:9/19/2014)... 19, 2014 BioTech News Coverage: ... and results of studies and trials.  Companies in focus ... (NYSE: LLY ), Gilead Sciences Inc. (NASDAQ: ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... prodrug therapeutics for the treatment of cancer, announced that ...
(Date:9/19/2014)... 2014 , The first grants ... Paediatric Endocrinology (ESPE) Meeting  Investment supports innovative ... in the field of growth  , EMD ... Germany , today announced the first recipients of ... awards were announced during a Satellite Symposium organized by ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... Research Council (BBSRC) have taken a step towards producing ... livestock - after successfully assembling the virus outside a ... the journal Proceedings of the National Academy of ... develop vaccines with useful new properties. Professor Polly ...
... are closer to reality with the creation of graphene-based ... Rice chemist James Tour lab has created thin films ... lighting. The research was reported in the online edition ... screens may be the "killer app" that finally puts ...
... DIEGO, Aug. 1, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... will present at the Canaccord Genuity Annual Growth Conference ... at the InterContinental Hotel in Boston. (Logo: ... of this presentation will be accessible in the Investors ...
Cached Biology Technology:Scientists take a step towards developing better vaccines for bluetongue 2Scientists take a step towards developing better vaccines for bluetongue 3Dream screens from graphene 2Dream screens from graphene 3
(Date:9/19/2014)... species which over thousands of years has adapted to the ... that makes the cold dangerous for you. , This is ... and the cold provoking substance, called nonylphenol, comes from the ... suspected of being a endocrine disruptor, but when entering the ... ability to protect the cells in its body from cold ...
(Date:9/19/2014)... plants regulate their symbiotic relationship with soil bacteria ... the plant structure from leaves into the roots ... the roots. This collaborative study was conducted by ... the Graduate University for Advanced Studies (SOKENDAI), and ... Japan. , Legumes, an important plant family ...
(Date:9/18/2014)... Bulletin study uses tree rings to document arroyo ... in northern New Mexico, USA. By determining burial dates ... were able to precisely date arroyo sedimentary beds 30 ... with aerial imagery, LiDAR, longitudinal profiles, and repeat surveys ... are deep, oversized channels that have vertical or steeply ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3For legume plants, a new route from shoot to root 2Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... a researcher, please contact the Communications and External Relations staff ... information on ORNL and its research and development activities, please ... a general media-related question or comment, you can send it ... New data available . . . The ...
... 2008 - The chairman of EUS2008 today announced ... will allow physicians to directly inject malignant tumors ... will be presented at the 16th International Symposium ... September 12-13. This technique, which uses a flexible ...
... The Defense News Media,Group,s, C4ISR Journal will host its ... Awards Banquet on October 16-17, 2008 at the Sheraton,Crystal ... the importance of C4ISR technology through,various conference sessions including:, ... Intel Gathering & Sharing for Homeland Defense/Civil Support ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, September 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, September 2008 3Anti-tumor therapy with endoscopic ultrasound may fight cancer more safely and effectively 2Annual C4ISR Integrated Conference and Big 25 Awards Banquet 2Annual C4ISR Integrated Conference and Big 25 Awards Banquet 3
... dispensers save space and organize ... and other garb. They are ... for small parts used in ... acrylic. Open-slot design for easy ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Soil Nematode microRNA ...
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
Biology Products: